Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients is a research paper published in Oncotarget (2022). On theSindex it has a DataRank of 0. It has been cited 17 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: P50 CA217674
NCI NIH HHS
Grant: R01 CA260857
NCI NIH HHS
Grant: R01 CA247441
NCI NIH HHS
Grant: R01 CA244845
European Commission
Grant: 260872
More Medicines for Tuberculosis
National Institutes of Health
Grant: 5R01CA260872-03
A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients
National Institutes of Health
Grant: 5R01CA260857-03
Multiplexed time domain fluorescence tomography of tumor biomarkers during immunotherapy
National Institutes of Health
Grant: 5P50CA217674-04
The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma
National Institutes of Health
Grant: 1R01CA247441-01A1
Vascularized tumor explants for drug testing
FWCI
1.88
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals